We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
Read MoreHide Full Article
Shares of AngioDynamics, Inc. (ANGO - Free Report) reached a new 52-week high of $26.00 on Jun 21, before closing the session marginally lower at $25.85.
Shares of the company have gained 152.2% in the past year compared with the industry’s 18.7% growth and the S&P 500's 36.9% rise.
AngioDynamics is witnessing an upward trend in its stock price, prompted by its robust fiscal 2021 third-quarter results. The company’s robust product line and strength in NanoKnife also buoy optimism. However, a stiff competitive landscape and strict regulatory environment are concerning for the company.
Image Source: Zacks Investment Research
Let's delve deeper.
Key Growth Drivers
Robust Product Line: AngioDynamics’ strong product suite raises optimism. The company’s product line includes ablation and fluid management systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, and venous products. Notably, the Oncology unit includes Microwave Ablation, Radiofrequency Ablation (RFA), NanoKnife, BioSentry Tract Sealant System, Alatus, StarBurst RFA devices, among others.
NanoKnife Driving Growth: AngioDynamics’ progress with its NanoKnife product line buoys optimism. The product previously received FDA clearance for surgical ablation of soft tissues. Also, the FDA had already granted the NanoKnife System a Breakthrough Device Designation under the 21st Century Cures Act. The company has also launched the NanoKnife 3.0 generator, which has been approved by the FDA.
In the third quarter of fiscal 2021, the company saw strong NanoKnife probe sales in the United States. The consistent positive momentum in the United States is being primarily driven by the company’s increased capital base and an awareness raised by the DIRECT study.
Strong Q3 Results: AngioDynamics’ solid third-quarter fiscal 2021 results raise market sentiments. In the quarter, the company continued reaping benefits from the Auryon Atherectomy System, a pathbreaking technology for the treatment of Peripheral Artery Disease. Moreover, the company saw revenue growth in two of its operating segments in the fiscal third quarter. Also, it witnessed a solid performance of its technology platforms, including strong sales growth in the AngioVac arm and robust sales in its Auryon suite. The company also submitted a 510(k) application to the FDA in April for the AlphaVac System, further buoying market optimism.
Downsides
Stringent Regulatory Environment: AngioDynamics is exposed to a stringent regulatory environment. Regulatory setbacks might dampen approvals for pipeline products, which will in turn hurt overall growth. The company is also facing regulatory delays in its Asian markets, which is a concern.
Stiff Competition: The medical device business is intensely competitive, and is characterized by rapid technological change, frequent product introductions and evolving customer requirements. AngioDynamics’ customers consider many factors when choosing among products, including features and reliability. AngioDynamics faces competition globally from a wide range of companies, which includes stalwarts like Boston Scientific Corporation (BSX - Free Report) . The company remains apprehensive that it may not be able to compete effectively, thus losing market share to its competitors.
Zacks Rank & Key Picks
Currently, AngioDynamics carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
Shares of AngioDynamics, Inc. (ANGO - Free Report) reached a new 52-week high of $26.00 on Jun 21, before closing the session marginally lower at $25.85.
Shares of the company have gained 152.2% in the past year compared with the industry’s 18.7% growth and the S&P 500's 36.9% rise.
AngioDynamics is witnessing an upward trend in its stock price, prompted by its robust fiscal 2021 third-quarter results. The company’s robust product line and strength in NanoKnife also buoy optimism. However, a stiff competitive landscape and strict regulatory environment are concerning for the company.
Let's delve deeper.
Key Growth Drivers
Robust Product Line: AngioDynamics’ strong product suite raises optimism. The company’s product line includes ablation and fluid management systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, and venous products. Notably, the Oncology unit includes Microwave Ablation, Radiofrequency Ablation (RFA), NanoKnife, BioSentry Tract Sealant System, Alatus, StarBurst RFA devices, among others.
NanoKnife Driving Growth: AngioDynamics’ progress with its NanoKnife product line buoys optimism. The product previously received FDA clearance for surgical ablation of soft tissues. Also, the FDA had already granted the NanoKnife System a Breakthrough Device Designation under the 21st Century Cures Act. The company has also launched the NanoKnife 3.0 generator, which has been approved by the FDA.
In the third quarter of fiscal 2021, the company saw strong NanoKnife probe sales in the United States. The consistent positive momentum in the United States is being primarily driven by the company’s increased capital base and an awareness raised by the DIRECT study.
Strong Q3 Results: AngioDynamics’ solid third-quarter fiscal 2021 results raise market sentiments. In the quarter, the company continued reaping benefits from the Auryon Atherectomy System, a pathbreaking technology for the treatment of Peripheral Artery Disease. Moreover, the company saw revenue growth in two of its operating segments in the fiscal third quarter. Also, it witnessed a solid performance of its technology platforms, including strong sales growth in the AngioVac arm and robust sales in its Auryon suite. The company also submitted a 510(k) application to the FDA in April for the AlphaVac System, further buoying market optimism.
Downsides
Stringent Regulatory Environment: AngioDynamics is exposed to a stringent regulatory environment. Regulatory setbacks might dampen approvals for pipeline products, which will in turn hurt overall growth. The company is also facing regulatory delays in its Asian markets, which is a concern.
Stiff Competition: The medical device business is intensely competitive, and is characterized by rapid technological change, frequent product introductions and evolving customer requirements. AngioDynamics’ customers consider many factors when choosing among products, including features and reliability. AngioDynamics faces competition globally from a wide range of companies, which includes stalwarts like Boston Scientific Corporation (BSX - Free Report) . The company remains apprehensive that it may not be able to compete effectively, thus losing market share to its competitors.
Zacks Rank & Key Picks
Currently, AngioDynamics carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>